WP
CASC

WealthPLAN Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

WealthPLAN Partners’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$2.8K Sell
278
-277
-50% -$1.96K ﹤0.01% 812
2016
Q2 		$1.57K Buy
+555
New +$3.77K ﹤0.01% 2274
2015
Q4 		$3.71K Buy
+833
New +$14.3K ﹤0.01% 1402
2015
Q2 		$6K Hold
278
– – ﹤0.01% 337
2015
Q1 		$2K Buy
+278
New +$2.73K ﹤0.01% 500

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

WealthPLAN Partners's CASC Position: Q3 2016 in Review

WealthPLAN Partners reduced its Cascadian Therapeutics, Inc. (CASC) stake by 50% in Q3 2016, selling an estimated $1.96K and leaving 278 shares worth $2.8K. The position accounts for ﹤0.01% of the portfolio, ranked #812.

WealthPLAN Partners first reported a position in CASC in Q1 2015 and has held it in 5 quarters since. The position peaked at $6K in Q2 2015. 77 funds tracked by Wall St. Rank hold CASC as of Q3 2016.

  • WealthPLAN Partners held 278 shares of Cascadian Therapeutics, Inc. worth $2.8K as of Q3 2016.
  • WealthPLAN Partners sold 277 Cascadian Therapeutics, Inc. shares in Q3 2016, an estimated $1.96K.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #812 holding.
  • WealthPLAN Partners first reported a position in Cascadian Therapeutics, Inc. in Q1 2015 and has held it in 5 quarters since.
  • WealthPLAN Partners's Cascadian Therapeutics, Inc. position peaked at $6K in Q2 2015.
  • 77 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.